GlobeNewswire Inc. · May 6, 2024
Telesis Bio Announces Reverse Stock Split
Telesis Bio Announces Reverse Stock Split
TB
OTC · TBIO
Telesis Bio, Inc.
Healthcare · Medical - Devices
$0.00
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 9:53 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.65M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $1.55
- Volume
- 8K
- Avg. volume
- 156
Price performance
TBIO price history
1M range · 0 trading sessions · Daily adjusted prices
TBIO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TBIO news
The latest Smart Investors Daily articles mentioning TBIO.
Stock researchCompany · Overview
TBIO research
Overview
Company profile and research snapshot.
Company profile
TELESIS BIO INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.08
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2023 | Keybanc | Sector Weight | — |
| Aug 4, 2021 | Roth Capital | Neutral | — |
| Aug 3, 2021 | William Blair | Market Perform | — |
| Aug 3, 2021 | SVB Leerink | Market Perform | — |
| Jul 26, 2021 | Roth Capital | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Mar 28, 2024
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense.
Zacks Investment Research · Feb 27, 2024
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire Inc. · Feb 26, 2024
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
